Scarica l'app Stockscreener
6.805
9.51%
-0.715
Precedente Chiudi:
$7.52
Aprire:
$7.627
Volume 24 ore:
158.68K
Relative Volume:
2.23
Capitalizzazione di mercato:
$159.45M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-8.41%
1M Prestazione:
+16.07%
6M Prestazione:
-20.69%
1 anno Prestazione:
-20.42%
Intervallo 1D:
$6.64
$7.70
Intervallo di 1 settimana:
$6.64
$7.90
Portata 52W:
$5.47
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Nome
Actuate Therapeutics Inc
Settore
Industria
Telefono
847-986-4190
Indirizzo
1751 RIVER RUN, FORT WORTH
Confronta ACTU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
6.86 | 174.79M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-26 | Iniziato | B. Riley Securities | Buy |
| 2025-04-22 | Iniziato | Craig Hallum | Buy |
| 2025-03-17 | Iniziato | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Borsa (ACTU) Ultime notizie
Actuate reports promising results for elraglusib in salivary cancer By Investing.com - Investing.com Nigeria
Actuate Therapeutics Announces Promising Phase II Study Results for Elraglusib in Advanced Salivary Gland Cancer - Quiver Quantitative
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma - GlobeNewswire
Voss Capital LP Purchases 143,759 Shares of Actuate Therapeutics, Inc. $ACTU - MarketBeat
Actuate Therapeutics, Inc. (ACTU)’s Elraglusib Elraglusib Trial Hits Key Goals in Pancreatic Cancer - MSN
Published on: 2025-12-07 08:30:16 - BỘ NỘI VỤ
Will Actuate Therapeutics Inc. stock see PE expansionInsider Selling & Daily Chart Pattern Signal Reports - Newser
Why Actuate Therapeutics Inc. stock is a must watch in 2025Forecast Cut & AI Based Buy and Sell Signals - Newser
Actuate Therapeutics enters $100 million at-the-market sales agreement - Investing.com
Actuate Therapeutics Signs $100M Sales Agreement - TipRanks
Actuate Therapeutics Inc enters at the market issuance sales agreement with B. Riley and Craig-HallumSEC filing - marketscreener.com
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% - Zacks Investment Research
Actuate Therapeutics enters $100 million at-the-market sales agreement By Investing.com - Investing.com UK
Why Actuate Therapeutics Inc. stock is recommended by analystsJuly 2025 Analyst Calls & Verified Technical Trade Signals - BỘ NỘI VỤ
What risks investors should watch in Actuate Therapeutics Inc. stockOptions Play & Weekly Setup with ROI Potential - moha.gov.vn
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap surged US$24m last week, private equity firms who have a lot riding on the company were rewarded - simplywall.st
BIOS Capital Management LP Buys 71,428 Shares of Actuate Therapeutics, Inc. $ACTU - Defense World
What analysts say about Actuate Therapeutics Inc stockTrade Execution Strategies & Daily Tips From Top Market Analysts - earlytimes.in
Will Upside Catalysts Materialize for Prime Industries Limited in YEARHigh Frequency Trading Trends & Free Unlock Rapid Growth Potential - earlytimes.in
HC Wainwright Has Bullish Estimate for ACTU FY2025 Earnings - Defense World
Why Actuate Therapeutics Inc. stock is in analyst buy zoneEarnings Trend Report & Verified Entry Point Signals - newser.com
Actuate Therapeutics (NASDAQ:ACTU) Given "Buy" Rating at HC Wainwright - MarketBeat
Actuate Therapeutics: Strategic Advancements and Financial Outlook Drive Buy Rating - TipRanks
HC Wainwright & Co. Reiterates Actuate Therapeutics (ACTU) Buy Recommendation - Nasdaq
How Actuate Therapeutics Inc. stock compares to market leadersEarnings Overview Report & Expert Approved Momentum Ideas - newser.com
Using R and stats models for Actuate Therapeutics Inc. forecastingRate Hike & Fast Gaining Stock Reports - newser.com
Strategies to average down on Actuate Therapeutics Inc.Quarterly Risk Review & Safe Capital Growth Stock Tips - newser.com
How Actuate Therapeutics Inc. stock benefits from tech adoptionTrade Volume Summary & Long-Term Growth Plans - newser.com
Actuate Therapeutics (NASDAQ:ACTU) Shares Up 0.5% After Better-Than-Expected Earnings - MarketBeat
Advanced analytics toolkit walkthrough for Actuate Therapeutics Inc.July 2025 Short Interest & Weekly Return Optimization Alerts - newser.com
Is it time to cut losses on Actuate Therapeutics Inc.July 2025 Update & High Yield Stock Recommendations - newser.com
Here's Why We're Watching Actuate Therapeutics' (NASDAQ:ACTU) Cash Burn Situation - Yahoo Finance
What indicators show strength in Actuate Therapeutics Inc.July 2025 Decliners & Advanced Technical Signal Analysis - newser.com
Actuate Therapeutics (NASDAQ:ACTU) Stock Price Up 0.5% on Better-Than-Expected Earnings - Defense World
Analysts Offer Insights on Healthcare Companies: Vicarious Surgical (RBOT) and Intensity Therapeutics, Inc. (INTS) - The Globe and Mail
Actuate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Analysts Offer Insights on Healthcare Companies: Tyra Bioscience (TYRA), Janux Therapeutics Inc (JANX) and Eledon Pharmaceuticals (ELDN) - The Globe and Mail
What’s next for Actuate Therapeutics Inc. stock priceJuly 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com
Actuate Therapeutics Inc Azioni (ACTU) Dati Finanziari
Non sono disponibili dati finanziari per Actuate Therapeutics Inc (ACTU). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):